Artery- and vein-specific proteins and uses therefor

Details Artery- and vein-specific proteins and uses therefor Artery- and vein-specific proteins and uses therefor

2005-07-15

2010-06-22

Nickol, Gary B (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S141100, C424S143100, C530S387100, C530S388100, C530S388220

Reexamination Certificate

active

07741272

ABSTRACT:
Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.

REFERENCES:
patent: 5512591 (1996-04-01), Halperin et al.
patent: 5624899 (1997-04-01), Bennett et al.
patent: 5635177 (1997-06-01), Bennett et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5770599 (1998-06-01), Gibson et al.
patent: 5795734 (1998-08-01), Flanagan et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5864020 (1999-01-01), Bennett et al.
patent: 6303769 (2001-10-01), Cerretti et al.
patent: 6413730 (2002-07-01), Holland et al.
patent: 6479459 (2002-11-01), Cerretti et al.
patent: 6492140 (2002-12-01), Cerretti et al.
patent: 6514497 (2003-02-01), Briskin et al.
patent: 6579683 (2003-06-01), Wang et al.
patent: 6864227 (2005-03-01), Wang et al.
patent: 6887674 (2005-05-01), Wang et al.
patent: 6916625 (2005-07-01), Wang et al.
patent: 7163808 (2007-01-01), Anderson et al.
patent: 2002/0146420 (2002-10-01), Bennett et al.
patent: 2003/0157712 (2003-08-01), Daniel et al.
patent: 2004/0136983 (2004-07-01), Aguet
patent: 2004/0234520 (2004-11-01), Aguet et al.
patent: 0 633 315 (1993-03-01), None
patent: 0999 278 (2000-05-01), None
patent: WO-93/00425 (1993-01-01), None
patent: WO 93/15201 (1993-08-01), None
patent: WO-94/10202 (1994-05-01), None
patent: WO-94/11020 (1994-05-01), None
patent: WO-95/27061 (1995-10-01), None
patent: WO-96/02645 (1996-02-01), None
patent: WO-96/03043 (1996-02-01), None
patent: WO 96/26958 (1996-02-01), None
patent: WO-96/09384 (1996-03-01), None
patent: WO-96/13518 (1996-05-01), None
patent: WO-96/23000 (1996-08-01), None
patent: WO 96/26958 (1996-09-01), None
patent: WO-96/36713 (1996-11-01), None
patent: WO-97/09427 (1997-03-01), None
patent: WO-97/23629 (1997-07-01), None
patent: WO-97/43960 (1997-11-01), None
patent: WO-97/44453 (1997-11-01), None
patent: WO 99/52541 (1998-04-01), None
patent: WO-98/45331 (1998-10-01), None
patent: WO 98/45708 (1998-10-01), None
patent: WO 99/08696 (1999-02-01), None
patent: WO-99/17796 (1999-04-01), None
patent: WO 00/24413 (2000-05-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO 02/11785 (2002-02-01), None
patent: WO 02/26827 (2002-04-01), None
patent: WO 02/058538 (2002-08-01), None
patent: WO 02/061055 (2002-08-01), None
patent: WO 02/079382 (2002-10-01), None
patent: WO 02/102973 (2002-12-01), None
patent: WO 03/004057 (2003-01-01), None
patent: WO-03/094859 (2003-11-01), None
patent: WO-2004/014292 (2004-02-01), None
patent: WO-2004/091375 (2004-10-01), None
patent: WO-2005/048917 (2005-06-01), None
patent: WO-2005/051307 (2005-06-01), None
Wang, Nat. Cell Biol., 2006, 8(8):785-786.
Fox et al., Biochem. Biophys. Res. Commun., 2004, 318(4):882-92.
Chrencik et al., J. Biol. Chem., Sep. 26, 2007, Epub.
Pasquale, E. B., Curr. Opin. Cell Biol., 1997, 9:608-615.
Xu et al., J. Mol. Med., 1997, 75:576-586.
Simonet et al., European J. Pharmacology, vol. 216, pp. 135-137, 1992.
Pasquale, Curr. Opin. Cell. Biol. vol. 9, pp. 608-618, 1997.
tBruckner et al., Science, vol. 275, pp. 1640-1643, 1997.
Dermer, Gerald B., “Another Anniversary for the War on Cancer,”Bio/Technology, 12:320 (1994).
Freshney, R. Ian, Culture of Animal Cells: A Manual of Basic Technique, pp. 3-4 (1983).
Gura, Trisha, “Systems for Identifying New Drugs Are Often Faulty,”Science, 278:1041-1042 (1997).
Stephenson, S.A., et al., “Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer,” BMC Mol. Biol., 2:15 (2001).
Santa Cruz Biotechnology, Inc., “EphB4 (N-19): sc-7285”, retrieved from the Internet: URL:http://www.genetimes.com.cn/support/pd f-ds/7200-7299/sc-7285.pdf (1999).
Inada et al., “Selective Expression of the Receptor Tyrosine Kinase, HTK, on Human Erythroid Progenitor Cells”, Blood, 89(8), pp. 2757-2765 (1997).
Fabes et al., “Accumulation of the Inhibitory Receptor EphA4 May Prevent Regeneration of Corticospinal Tract Axons Following Lesion”Eur. J. Neurosci., 23(7):1721-1730 (2006) (Abstract).
Pandey et al., “Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF-a-Induced Angiogenesis”, Science, vol. 268, pp. 567-569 (1995).
Sturz, et al., “EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration”, Biochemical and Biophysical Research Communications, vol. 313, pp. 80-88 (2004).
Yuan, et al., “Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis”, Blood, vol. 104(4), pp. 1025-1033 (2004).
Gerety, S.S., et al., “Symmetrical Mutant Phenotypes of the ReceptorEphB4and Its Specific Transmembrane Ligandephrin-B2in Cardiovascula Development,”Mol. Cell, 4:403-414 (1999).
Gale, N.W., et al., “Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells,”Dev. Biol., 230: 151-160 (2001).
Adams, R.H., et al., “Roles of EphrinB Ligands and EphB Receptors in Cardiovascular Development: Demarcation of Arterial/Venous Domains, Vascular Morphogenesis, and Sprouting Angiogenesis,”Genes Dev. 13:295-306 (1999).
Henkemeyer, M., et al., “Nuk Controls Pathfinding of Commissural Axons in the Mammalian Central Nervous System,”Cell, 86:35-46 (1996).
Orioli, D., et al., “Sek4 and Nuk Receptors Cooperate in Guidance of Commissural Axons and in Palate Formation,”Embo J., 15(22):6035-6049 (1996).
Stein, E. et al., “Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses,”J. Of Cellular and Molecular Biology, 12(5):667-678 (1998).
Stein, E. et al., “Nck Recruitment to Eph Receptor, EphB1/ELK, Couples Ligand Activation to c-Jun Kinase,”The Journal of Biological Chemistry, 273(3):1303-1308 (1998).
Simonet, S., et al., “Venous and Arterial Endothelial Cells Respond Differently to Thrombin and its Endogenous Receptor Agonist,”European Journal of Pharmacology 216: 135-137 (1992).
Yancopoulos, G.D., et al., “Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border,”Cell, 93: 661-664 (1998).
Wang, H., “Transmembrane Ephrin Ligands in Neural and Vascular Development,”DAI, 59(11): 5721 (1999).
Bennett, B. D. et al., “Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1866-1870, Mar. 1995.
Bergemann, A. D. et al., “ELF-2, a New Member of the Eph Ligand Family, Is Segmentally Expressed in Mouse Embroys in the Region of the Hindbrain and Newly Forming Somites,”Molecular and Cellular Biology, vol. 15, No. 9, pp. 4921-4929, Sep. 1995.
Stein, E. et al., “Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses,”Genes&Development 12:667-678, 1998.
Andres, A. C. et al., “Expression of two noveleph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis,”Oncogene, vol. 9, pp. 1461-1467, 1994.
Folkman, J. et al., “Blood Vessel Formation: What Is Its Molecular Basis?,”Cell, vol. 87, pp. 1153-1155, Dec. 27, 1996.
Risau, W., Mechanisms of angiogenesis,Nature, vol. 386, pp. 671-674, Apr. 17, 1997.
Pasquale, E. B., “The Eph family of receptors,”Curr. Opin. Cell. Biol. 9:608-615, 1997.
Wang, H. U. et al., “Eph Family Transme

Affiliated with

Also associated with

Rating

Artery- and vein-specific proteins and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Artery- and vein-specific proteins and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Artery- and vein-specific proteins and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4176889